Abeona Therapeutics Inc. (ABEO)
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for life-threatening rare genetic diseases. Their lead program, EB-101, is in Phase III clinical trials for recessive dystrophic epidermolysis bullosa.
Company Overview
Abeona Therapeutics pioneers gene and cell therapies for rare genetic diseases, offering a high-risk, high-reward investment opportunity with its Phase III lead program EB-101 targeting recessive dystrophic epidermolysis bullosa and a robust pipeline addressing unmet medical needs, reflected in a P/E ratio of 3.23.
Investment Thesis
Abeona Therapeutics presents a compelling, albeit high-risk, investment opportunity within the gene and cell therapy space. The company's lead asset, EB-101, nearing potential commercialization following Phase III trials, addresses a significant unmet need in recessive dystrophic epidermolysis bullosa. Positive clinical data and eventual market approval could drive substantial revenue growth. Furthermore, Abeona's diversified pipeline targeting other rare genetic diseases offers additional upside potential. The company's current P/E ratio of 3.23 may indicate undervaluation, assuming successful commercialization of its therapies. Key value drivers include positive clinical trial outcomes, regulatory approvals, and strategic partnerships. Investors should consider the inherent risks associated with clinical-stage biopharmaceutical companies, including clinical trial failures and regulatory hurdles. The company's gross margin of -241.0% highlights the need for successful product commercialization.
Key Highlights
- EB-101 is in Phase III clinical trials for recessive dystrophic epidermolysis bullosa, representing a near-term value driver.
- Abeona's pipeline includes multiple AAV-based gene therapies targeting rare genetic diseases, diversifying its product portfolio.
- The company's AIM vector platform offers potential for developing novel gene therapies.
- Abeona's market capitalization is $0.27 billion, reflecting its current stage of development.
- The company's profit margin is 20587.5%, which may be due to a one-time event.
Competitors
Strengths
- Proprietary gene and cell therapy platforms.
- Advanced clinical-stage pipeline.
- Focus on rare genetic diseases with unmet needs.
- Experienced management team.
Weaknesses
- High research and development costs.
- Dependence on clinical trial outcomes.
- Regulatory hurdles and approval timelines.
- Limited commercialization experience.
Catalysts
- Upcoming: EB-101 Phase III clinical trial data readout.
- Upcoming: Regulatory submissions for EB-101.
- Ongoing: Advancement of pipeline programs through clinical trials.
- Ongoing: Strategic partnerships and collaborations.
Risks
- Potential: Clinical trial failures.
- Potential: Regulatory delays or rejections.
- Potential: Competition from other gene and cell therapy companies.
- Ongoing: High cash burn rate.
- Ongoing: Dependence on key personnel.
Growth Opportunities
- EB-101 Commercialization: Successful completion of Phase III trials and subsequent FDA approval for EB-101 represents a significant growth opportunity. The market for RDEB therapies is currently underserved, and EB-101 could capture a substantial share, potentially generating significant revenue within the next 2-3 years. This hinges on positive clinical outcomes and efficient manufacturing and distribution capabilities.
- Pipeline Expansion: Abeona's pipeline of gene and cell therapies targeting Sanfilippo syndrome type A (ABO-102), CLN3 disease (ABO-201), cystic fibrosis (ABO-401), and genetic eye disorders (ABO-50X) offers substantial growth potential. Positive clinical data and regulatory approvals for these programs could significantly expand Abeona's product portfolio and revenue streams over the next 3-5 years.
- Strategic Partnerships: Collaborating with larger pharmaceutical companies or research institutions could accelerate the development and commercialization of Abeona's therapies. Strategic partnerships can provide access to funding, expertise, and established distribution networks, enhancing Abeona's competitive position and market reach within the next 1-2 years.
- AIM Vector Platform: Leveraging its AIM vector platform to develop novel gene therapies for a wider range of genetic diseases represents a long-term growth opportunity. This platform could enable Abeona to expand its pipeline beyond its current focus and address unmet medical needs in various therapeutic areas over the next 5+ years.
- Geographic Expansion: Expanding into international markets, particularly Europe and Asia, could drive revenue growth for Abeona's therapies. Establishing a presence in these markets would require regulatory approvals and strategic partnerships, but could significantly increase the company's addressable market within the next 3-5 years.
Opportunities
- Expanding pipeline through internal development and acquisitions.
- Strategic partnerships with larger pharmaceutical companies.
- Geographic expansion into international markets.
- Advancements in gene and cell therapy technologies.
Threats
- Clinical trial failures.
- Regulatory setbacks.
- Competition from other gene and cell therapy companies.
- Ethical concerns surrounding gene therapy.
Competitive Advantages
- Proprietary gene and cell therapy technologies.
- Patent protection for their therapies.
- Orphan drug designation for certain therapies, providing market exclusivity.
- Expertise in developing therapies for rare genetic diseases.
About
Abeona Therapeutics Inc., founded in 1974 and rebranded in June 2015, is a clinical-stage biopharmaceutical company dedicated to developing innovative gene and cell therapies for rare and life-threatening genetic diseases. The company's mission is to provide potentially curative treatments for patients with limited or no therapeutic options. Abeona's lead program, EB-101, is an autologous, gene-corrected cell therapy currently in Phase III clinical trials for recessive dystrophic epidermolysis bullosa (RDEB), a devastating skin blistering condition. Beyond EB-101, Abeona is advancing a diverse pipeline of gene and cell therapies targeting other rare genetic diseases, including Sanfilippo syndrome type A (ABO-102), CLN3 disease (ABO-201), cystic fibrosis (ABO-401), and genetic eye disorders (ABO-50X). These programs utilize both adeno-associated virus (AAV)-based gene therapy and the company's AIM vector platform. Headquartered in Cleveland, USA, Abeona is committed to translating scientific breakthroughs into transformative therapies for patients in need. The company's evolution from PlasmaTech Biopharmaceuticals to Abeona reflects its strategic shift towards gene and cell therapy development, positioning it as a key player in the rapidly evolving field of rare disease therapeutics.
What They Do
- Develop gene therapies for rare genetic diseases.
- Develop cell therapies for rare genetic diseases.
- Focus on life-threatening conditions with unmet medical needs.
- Advance EB-101, a gene-corrected cell therapy, for recessive dystrophic epidermolysis bullosa (RDEB).
- Develop AAV-based gene therapies for Sanfilippo syndrome type A, CLN3 disease, cystic fibrosis, and genetic eye disorders.
- Utilize the AIM vector platform for gene therapy development.
- Conduct clinical trials to evaluate the safety and efficacy of their therapies.
- Seek regulatory approvals from agencies like the FDA.
Business Model
- Develop and patent gene and cell therapy technologies.
- Conduct clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval for their therapies.
- Commercialize approved therapies through direct sales or partnerships.
Industry Context
Abeona Therapeutics operates within the rapidly growing gene and cell therapy market, which is projected to reach billions of dollars in the coming years. This market is driven by advancements in genetic engineering and a growing understanding of the underlying causes of genetic diseases. The competitive landscape includes companies like ARCT, ASMB, ELDN, FHTX and HUMA, all focused on developing innovative therapies for various diseases. Abeona's focus on rare genetic diseases differentiates it from some competitors targeting more common conditions. The industry is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies.
Key Customers
- Patients with rare genetic diseases.
- Hospitals and medical centers.
- Specialty pharmacies.
- Healthcare providers.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $400,000 | $109M | $0.00 |
Source: Company filings
Chart & Info
Price Chart
Abeona Therapeutics Inc. (ABEO) stock price: $5.03 (+0.00, +0.00%)
Why Bull
- •Recent insider buying suggests confidence in ABEO's future, indicating that those closest to the company believe in its potential.
- •Community sentiment has shifted positively, with many traders expressing optimism about upcoming product developments.
- •The company has made strides in its clinical trials, attracting attention and fostering hope among investors for successful outcomes.
- •Increased media coverage has highlighted ABEO's innovative approach, enhancing its visibility and appeal in the market.
Why Bear
- •Concerns about the long timeline for clinical trial results have created uncertainty among investors, dampening enthusiasm.
- •Social sentiment has also revealed skepticism regarding the sustainability of recent gains, with some traders expressing caution.
- •Market perception remains cautious due to historical volatility, leading to hesitance in fully committing to the stock.
- •Recent discussions in trading forums indicate a divide, with a notable portion of the community questioning the long-term viability of ABEO's strategies.
Latest News
-
Netflix Is Casting a Light on a Rare Disease. Pearl Jam’s Frontman Is Raising Cash to Cure It.
Barrons.com · Feb 14, 2026
-
Insider-Favored Growth Companies To Watch February 2026
Simply Wall St. · Feb 2, 2026
-
63 Biggest Movers From Friday
· Dec 20, 2021
-
Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018
· Dec 20, 2018
Technical Analysis
Rationale
AI-generated technical analysis for ABEO including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Abeona Therapeutics Inc. (ABEO) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for ABEO.
Make a Prediction
Set your price target for Abeona Therapeutics Inc. (ABEO), choose a timeframe, and track your prediction accuracy.
Current price: $5.03
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ABEO.
Price Targets
Wall Street price target analysis for ABEO.
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 5/100
Revenue growth data is currently unavailable for this company.
-
Gross Margin 5/100
Gross margin data is currently unavailable for this company.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 3/100
Net insider selling of -$18.10M may indicate reduced confidence or routine diversification by executives.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
News sentiment is mixed, with a balance of positive and negative coverage in recent days.
What does this score mean?
The MoonshotScore rates ABEO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Netflix Is Casting a Light on a Rare Disease. Pearl Jam’s Frontman Is Raising Cash to Cure It.
Insider-Favored Growth Companies To Watch February 2026
63 Biggest Movers From Friday
Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018
Frequently Asked Questions
What does Abeona Therapeutics Inc. do?
Abeona Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of gene and cell therapies for rare and life-threatening genetic diseases. Their primary focus is on advancing EB-101, a gene-corrected cell therapy currently in Phase III trials for recessive dystrophic epidermolysis bullosa (RDEB). Beyond EB-101, Abeona is developing a pipeline of AAV-based gene therapies targeting other rare genetic diseases, utilizing their proprietary AIM vector platform. The company aims to provide potentially curative treatments for patients with limited or no existing therapeutic options, addressing significant unmet medical needs.
Is ABEO stock a good buy?
ABEO stock represents a high-risk, high-reward investment opportunity. The potential success of EB-101 in treating RDEB could drive significant value. However, investors should be aware of the inherent risks associated with clinical-stage biopharmaceutical companies, including the possibility of clinical trial failures and regulatory setbacks. While the company's P/E ratio of 3.23 might suggest undervaluation, it's crucial to consider the negative gross margin of -241.0%, highlighting the need for successful product commercialization to justify the investment. Thorough due diligence is essential before investing in ABEO.
What are the main risks for ABEO?
Abeona Therapeutics faces several key risks common to clinical-stage biopharmaceutical companies. Clinical trial failures represent a significant risk, as negative data could halt the development of their therapies. Regulatory hurdles and potential delays in obtaining FDA approval also pose a threat. Competition from other gene and cell therapy companies is intensifying, potentially impacting Abeona's market share. Additionally, the company's high cash burn rate and dependence on key personnel could create financial and operational challenges. Investors should carefully consider these risks before investing in ABEO.
Is ABEO a good stock to buy?
Whether ABEO is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the ABEO MoonshotScore?
The MoonshotScore for ABEO is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is ABEO data updated?
ABEO stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to ABEO is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for ABEO?
Growth catalysts for Abeona Therapeutics Inc. (ABEO) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Abeona Therapeutics Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are ABEO's main competitors?
Abeona Therapeutics Inc. (ABEO) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether ABEO has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about ABEO?
Wall Street analyst coverage for ABEO includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is ABEO's market cap?
Market capitalization (market cap) for ABEO is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows ABEO's current market cap alongside enterprise value and other valuation metrics.
How has ABEO stock performed recently?
ABEO's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing ABEO's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in ABEO?
Key risk categories for ABEO include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures ABEO's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling ABEO?
Insider trading activity for ABEO tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is ABEO a good stock for beginners?
Abeona Therapeutics Inc. (ABEO) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is ABEO for first-time investors?
Every stock carries risk, including Abeona Therapeutics Inc. (ABEO). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like ABEO.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change. Investment decisions should be made based on individual risk tolerance and thorough due diligence.